The FDA, Preemption, and Public Safety

Abstract

Most people think of preemption as a technical, constitutional doctrine, but it is pivotally important to health and safety and opens the door to broad judicial discretion. The Rehnquist and Roberts Courts' jurisprudence, with its support for both business and preemption, has been distinctly antiregulatory, invalidating major state public health rules in occupational safety, tobacco control, and motor vehicle safety, among other things. (1) And apart from these antiregulatory stances, the Supreme Court has also been maddeningly inconsistent. Consider three relatively recent cases. In its 2008 decision in Riegel v. Medtronic, Inc., the Court held that federal law bars injured consumers from challenging the safety or effectiveness of medical devices approved by the Food and Drug Administration. (2) A year later, however, in Wyeth v. Levine, the Court came to the opposite conclusion, ruling that injured consumers could sue pharmaceutical companies for failing to warn about the risks of taking brand-name drugs. (3) Yet on June 23, 2011, in PLIVA, Inc., v. Mensing, the Court found that injured consumers could not bring failure-to-warn claims for injuries caused by FDA-approved generic pharmaceuticals. (4) Thus, in less than four years, the Court barred state health and safety litigation for FDA-approved medical devices, allowed failure-to-warn claims for branded pharmaceuticals, and then barred those same claims for generic pharmaceuticals. (5) What is the rational basis for treating brand-name and generic medicines differently when, by the products must be equivalent? Or for treating brand-name drugs and medical devices differently even though they go through similar approval processes? As Justice Sotomayor (dissenting in PLIVA) put it, this leads to so many absurd consequences that I cannot fathom that Congress would have intended to preempt state law, while even Justice Thomas, writing for the Court, admitted this outcome makes little sense. In order to figure out how we reached this predicament, let's take a step back and find out more about the perversion of the preemption doctrine, the newest ruling on generic medicines, and the public health value of consumer litigation. Public Health and Preemption Preemption is a doctrine undergirded by the supremacy clause, which holds that federal law prevails over state law if there is a conflict. The two cornerstones of preemption are Congress's intent as the ultimate touchstone and the strong presumption against preemption when the state exercises its historic police powers. The Supreme Court has repeatedly perverted these two key criteria. Congress intended for federal and state food and drug regulation to work side by side, each providing a significant yet distinct layer of consumer protection. If Congress thought state lawsuits posed an obstacle to its objectives, it surely would have said so explicitly at some point during the Food, Drug, and Cosmetic Act's seventy-year history. How could Congress have intended such irrational inconsistencies between brand-name and generic drugs? Is it reasonable for the nation's highest court to conclude that Congress actually intended to bar injured patients from judicial recourse against companies that, knowing the risks, aggressively market hazardous drugs or medical devices? The public might express even greater skepticism if tort immunity were granted to corporations that defraud the agency. But that is precisely the position of the Supreme Court, which permits a corporation to use FDA approval as a shield against litigation even if it deceived the agency into granting that approval. In Buckman Company v. Plaintiffs' Legal Committee, the Court held that state law fraud-on-the-FDA claims were preempted. (6) The Court split four against four when asked if consumer litigation was also preempted when drug companies defraud the agency. (7) Since Chief Justice Roberts did not participate in the decision, the Court would likely side with the pharmaceutical industry, even if it intentionally hides safety data. …